It's faster, and done right, good for everyone at the table. So why does the PMCPA's Abridged Procedure remain the road less travelled? Rina & Jean investigate the case for using it more: the benefits for companies facing complaints, for complainants seeking resolution, and for the PMCPA itself. If it works this well, what's holding the PMCPA back?

The PMCPA has released its 2025 Annual Report - but does the data point to a genuinely transformational year, or business as usual? In this episode, Rina & Jean dig into the numbers to ask the question everyone in pharma is thinking: are companies actually getting more compliant, or are complaints simply getting worse?

Whether you are a new or seasoned signatory, the question of signatory standards is worth considering. Two experienced signatories (Rina & Jean) chat about 3 of the most important standards (the full 10 will be discussed in detail at our subscribers webinar on 17 Sept 26 - get in touch at [email protected] if you are not a subscriber).

Why does this matter to you? Because for the first time 'it happened ages ago' is now a legitimate defence (within limits). PMCPA Q&A on policy here.

No boring Code training: Rina & Jean summarise their webinar (free for subscribers) on Social Media Case ruling trends. To subscribe contact [email protected]

One third-party event, three pharma company sponsors & three complaints. All about the same thing - sponsorship declarations. If you organise third party events sponsored by pharma, Rina & Jean summarise what you can do to make compliance easier. (Cases/0556/04/25;/0557/04/25 & /0558/04/25)

A recent ruling found a MSL presenting at a promotional meeting no breach but why? Was it a technicality or a new PMCPA position?

Rina & Jean discuss the criteria in determing if a meeting is compliant. Venue is only one!

Rina & Jean discuss a recently published PMCPA ruling vs GSK about their corporate ad - placed before a finance podcast for the public. Was this actually promotion to the public or genuinely good corporate affairs work?

Theramex is the third UK pharma company to leave PMCPA jurisdiction in three years (Sandoz 2023, Evolus 2024, Theramex 2026).

Does that reflect increasing rules, companies avoiding audit, or self-regulation management of issues?

Rina & Jean discuss how we got here and what it means for the future of self-regulation.